i3 Health’s Post

When you’re under pressure to make critical decisions, you need a system innovated to rise to the challenge. Whether you're progressing high potency drug candidates into clinical trials, staying prepared for changing #PFAS regulations, or investing years in researching a biomarker that could later be used to help develop a diagnostic cancer test in a diagnostic application, the decisions you make count. 𝗙𝗲𝗮𝘁𝘂𝗿𝗶𝗻𝗴 1. Mass Guard Technology 2. Removable DJet+ assembly 3. Speeds of up to 800 MRM per second Find out more about the high sensitivity, speed and resilience offered by our new 𝗦𝗖𝗜𝗘𝗫 𝟳𝟱𝟬𝟬+ 𝘀𝘆𝘀𝘁𝗲𝗺 across large, complex sample sets. Visit our new product page to learn more 👉 https://bit.ly/3R8A5GF 𝗦𝗖𝗜𝗘𝗫. 𝗪𝗵𝗲𝗻 𝗶𝘁 𝗰𝗼𝘂𝗻𝘁𝘀. #SCIEX7500Plus #ASMS2024 #SCIEXforScience #FutureOfMassSpec #Innovation #MassSpectrometry

💊𝗪𝗲𝗹𝗰𝗼𝗺𝗲 𝗮 𝗪𝗲𝗮𝗹𝘁𝗵 𝗼𝗳 𝗗𝗲𝗻𝗼𝘀𝘂𝗺𝗮𝗯 𝗢𝗽𝘁𝗶𝗼𝗻𝘀💊   Explore our batch library and access 8 historical batches of clinical-grade Denosumab (Prolia®), ready to support your research and early drug develoment project. Here’s what we have for you:   ✅ 8 historical batches available now. ✅ Custom Aliquotation Service (CAS): Need fresh batches for specific projects? We’ve got you covered!   Why Denosumab? 🩺 🔹Treats osteoporosis and reduces fracture risk 🔹Effective for managing bone loss in cancer patients 🔹Blocks RANKL protein to improve bone strength   💻 Visit our website (link in the comments) to explore our full batch library and learn how our solutions can accelerate your research and drug development projects.   #ClinicalGradeMolecules #Denosumab #DrugDevelopment #Biosimilars #OsteoporosisTreatment #BoneMetastases #Innovation #ResearchAndDevelopment #Evidentic

🚀 𝗨𝗻𝗹𝗼𝗰𝗸𝗶𝗻𝗴 𝘁𝗵𝗲 𝗣𝗼𝘄𝗲𝗿 𝗼𝗳 𝗣𝗥𝗢𝗧𝗔𝗖𝘀 𝘄𝗶𝘁𝗵 𝗔𝘂𝗿𝗶𝗴𝗲𝗻𝗲’𝘀 𝗘𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲 🚀  With a decade of experience in integrated drug discovery, from the precision synthesis of PROTACs to in-depth molecular profiling. Our comprehensive capabilities, including Computer-Aided Drug Design (CADD) and expertise in molecular glues, empower us to deliver impactful therapeutic solutions.    💡 𝗪𝗵𝘆 𝗣𝗮𝗿𝘁𝗻𝗲𝗿 𝘄𝗶𝘁𝗵 𝗔𝘂𝗿𝗶𝗴𝗲𝗻𝗲?  🌟𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗧𝗲𝗰𝗵𝗻𝗶𝗾𝘂𝗲𝘀: Advanced synthetic methodologies for high-purity PROTAC synthesis.  🌟𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗣𝗿𝗼𝗳𝗶𝗹𝗶𝗻𝗴: Comprehensive analysis for robust efficacy and safety data.  🌟𝗘𝗻𝗱-𝘁𝗼-𝗘𝗻𝗱 𝗦𝘂𝗽𝗽𝗼𝗿𝘁: Seamless integration across the discovery, development, and optimization phases.    🌱 Join us on this journey and take your PROTACs to the next phase  Explore how we are advancing the boundaries of targeted therapy through PROTAC innovation. Together, we’re shaping a future where precision medicine leads the way in cancer treatment.  🔗 Learn more: https://lnkd.in/gQcjmwvU 📧 Reach out to us: contactapsl@aurigeneservices.com #AurigenePharmaceuticals #PROTACs #DrugDiscovery #Innovation #TargetedTherapies #HealthcareAdvancement

We’re pleased to provide an update on the progress of our Phase II clinical program for #RVU120, Ryvu’s first-in-class dual CDK8/19 inhibitor targeting hematologic malignancies:   ✅ All four Phase II studies were successfully launched in 2024: #RIVER-52, #RIVER-81, #POTAMI-61, and #REMARK. All progressing on track. ✅ Over 110 sites are expected to be activated by the end of 2024. ✅ Patient enrollment is accelerating and is expected to reach nearly 100 patients treated by the year-end.   ✅ RVU120 continues to demonstrate a favorable safety profile and better tolerability compared to most therapies for similar hematologic indications.   ✅ Positive signals observed, with more data expected to build on these initial findings.   With enrollment momentum growing, we anticipate key efficacy data from all four studies in H1 2025, which will provide a solid foundation for further updates.   This progress reflects the hard work of our team and the strong interest from the global investigator community.   👉 Learn more about our update on the RVU120 Phase II program: https://lnkd.in/dFG74R8R   #RyvuTx #RVU120 #biotech #ClinicalDevelopment #OncologyResearch     ❗ Don’t miss the chance to hear directly from Ryvu’s leadership team! Join us live on December 12 at 10:00 AM CET for the conference: https://lnkd.in/dvasfiKT

The drug development process can take up to 15 years, with 97% of cancer clinical trials failing. As a result, life sciences organizations are investing heavily in multi-modal data sets like #clinicogenomics to gain insights into how different patient populations respond to therapies in real-world settings. Combining COTA's deep clinical data sourced from EHRs with Guardant Health's extensive real-world longitudinal serial testing data, drug developers can facilitate biomarker discovery, refine clinical trials, accelerate approvals, and bring targeted, life-saving treatments to market more quickly. Read the full announcement. Link in comments 👇 #rwd #realworlddata #oncologyresearch

🌟 Insightful morning at the Transform Alliance event on Advanced Therapy Medicinal Products (#ATMPs)! 💡The TRANSFORM Alliance Conference brought together experts, policymakers, and advocates to delve into the critical advancements and challenges shaping the future of ATMPs. Together, they explored the legislative, regulatory, and practical steps needed to ensure these groundbreaking treatments reach the #patients. 📍 Key discussions included: 🔸 Taking stock of the current legislative and regulatory landscape for ATMPs 🔸 Unpacking the potential of the #PharmaceuticalPackage and the forthcoming #EUHTA Regulation 🔸 Addressing the complexities of delivering #CellTherapies to patients with #ChronicConditions and #Cancer 🔸 Shaping the future environment for the development and delivery of ATMPs 👉 More information about the event: https://lnkd.in/e5XfpZRH #ATMPs #Innovation #Healthcare #CellAndGeneTherapy #RareDiseses

The development of successful therapies necessitates the assessment of a drug's effect on multiple cells or tissue types. Modelling these complex interactions is often acheieved at the expense of scalability, thus posing a challenge for drug development. At HUB, we set up unique organoid co-cultures to allow the development of immunomodulatory agents within the tumor microenvironment. Want to discuss how this could help your research? Join us at #AACR2024. Our organoid expert will be happy to assist you in how our proprietary technology can help you move your immunotherapy agent to the clinical trials with confidence. Click in the link below to book a meeting with us --> https://bit.ly/4atqvWf #organoids #AACR2024 #cancerresearch #tumoroids #tumororganoids #patientinalab #oncologytrials #drugdevelopment #cocultures #tumormicroenvironment #immunecells #immunotherapy #immunecheckpointinhibitors #PDL1 #KRAS

Together towards success: Client experiences ⭐ We love hearing from our clients! Recently, we had the pleasure of working with NanoEcho on their innovative solution for rectal cancer diagnosis. Their feedback highlights our commitment to guiding companies through complex regulatory landscapes, ensuring that their groundbreaking products meet all necessary compliance standards. “RegSmart has been very helpful for us in understanding the regulatory requirements for our innovative solution, especially for setting up the clinical studies for the combination product. Since classification and claims impact the regulatory route we need to follow, they also affect the cost and time to market. Therefore, RegSmart’s experience with combination products and their scientific understanding has been valuable in helping us find the optimal path forward.” - Dr. Ulrika Axelsson, Clinical Director at NanoEcho We are proud to be a trusted partner in their journey. Check out their testimonial to see how we can help you navigate your regulatory challenges! 👉 RegSmart - Testimonial: https://lnkd.in/dEcqtCi6 #CustomerSuccess #Testimonials #RegulatoryAffairs #Pharma #MedTech

Accelerating Cancer Drug Development with Predictive Precision Medicine! Predictive precision medicine isn't just about better treatment; it's also about faster drug development. By using ex vivo drug response profiling and advanced algorithms, we can repurpose shelved drugs and identify effective treatments more quickly. This means more personalized therapies and faster access to life-saving medications for patients. #DrugDevelopment #CancerResearch #PrecisionMedicine #HealthcareInnovation #PatientCare https://lnkd.in/gyiMpRAn

IV medicines Can Be Turned into Pills Without Losing Effectiveness Injectables are widely used in medical practice, but for most patients, this is an inconvenient or unavailable option because it requires regular hospital visits. For example, cancer patients spend many hours in hospitals to receive chemotherapy through an IV. Scientists at Stanford have solved this problem in an elegant way - they have developed a special chemical tag that first marks the drug as water-soluble, and then as fat-soluble. Initial experiments have shown that this technology dramatically increases the bioavailability and effectiveness of drugs. https://lnkd.in/ezXju4EB